FDA Clinical Practices Oversight Will Move To Risk-Based Approach
Executive Summary
FDA will develop a risk-based system for overseeing clinical practices, Director of Good Clinical Practice Programs David Lepay, MD/PhD, said
You may also be interested in...
Centralized IRB System Could Speed Product Development, Merck Tells CBER
A centralized institutional review board process could speed product development and reduce unnecessary paperwork, Merck regulatory affairs official Mark Bagarazzi said
Centralized IRB System Could Speed Product Development, Merck Tells CBER
A centralized institutional review board process could speed product development and reduce unnecessary paperwork, Merck regulatory affairs official Mark Bagarazzi said
FDA Foreign Trials Proposed Rule Drops Reliance On Helsinki Declaration
FDA is proposing to revise its requirements for accepting data from foreign trials not conducted under an IND